5 -5 (91) 2026 - Kurbaniyazova M.Z., Yavbasarova D.B. - MODERN CONCEPTS OF THE IMPACT OF HYPERPROLACTINEMIA ON FEMALE REPRODUCTIVE FUNCTION

MODERN CONCEPTS OF THE IMPACT OF HYPERPROLACTINEMIA ON FEMALE REPRODUCTIVE FUNCTION

Kurbaniyazova M.Z. - Urgench State Medical Institute

Yavbasarova D.B. - Urgench State Medical Institute

Resume

Hyperprolactinemia is one of the most significant neuroendocrine disorders in women of reproductive age and plays a significant role in endocrine infertility, menstrual irregularities, hypogonadism, and sexual dysfunction. Elevated prolactin levels disrupt the regulation of the hypothalamic-pituitary-ovarian axis, suppress pulsatile secretion of gonadotropin-releasing hormone, and reduce the production of luteinizing hormone and follicle-stimulating hormone, leading to anovulation, luteal phase insufficiency, and decreased fertility. Current literature emphasizes that hyperprolactinemia should be considered not only as a laboratory abnormality but also as a clinical syndrome encompassing reproductive, metabolic, psychoemotional, and somatic manifestations. The mainstay of therapy is dopamine agonists, primarily cabergoline, which is considered a first-line drug for symptomatic hyperprolactinemia, prolactinomas, and idiopathic forms of the disease. Along with hormonal correction, non-hormonal approaches are important: normalizing sleep, reducing stress, weight management, treating concomitant endocrine disorders, and eliminating drug-induced causes of hyperprolactinemia.

Keywords: prolactin, hyperprolactinemia, prolactinoma, female infertility, anovulation, cabergoline.

First page

31

Last page

35

For citation:Kurbaniyazova M.Z., Yavbasarova D.B. - MODERN CONCEPTS OF THE IMPACT OF HYPERPROLACTINEMIA ON FEMALE REPRODUCTIVE FUNCTION//New Day in Medicine 5(91)2026 31-35 https://newdayworldmedicine.com/en/new_day_medicine/5-91-2026

List of References

1. Auriemma RS, Pirchio R, De Alcubierre D, Pivonello R, Colao A. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023;108(9):2400-2415. doi:10.1210/clinem/dgad174.
2. Benetti-Pinto CL, Ferreira SRG, Yela DA. Treatment of hyperprolactinemia in women. Arch Endocrinol Metab. 2024;68:1-12.
3. Benetti-Pinto CL, Soares PM. Hyperprolactinemia in women: treatment. Rev Bras Ginecol Obstet. 2024;46:1-10.
4. Capozzi A, Scambia G, Pontecorvi A, Lello S. Hyperprolactinemia: pathophysiology and therapeutic approach. Gynecol Endocrinol. 2015;31(7):506-510.
5. De Berardis D, Fornaro M, Serroni N, Campanella D, Rapini G, Olivieri L, et al. Treatment of antipsychotic-induced hyperprolactinemia: an update. CNS Neurol Disord Drug Targets. 2016;15(1):64-69.
6. De Sousa SMC, McCormack AI. Dopamine agonist therapy in prolactinomas: when can treatment be withdrawn? Pituitary. 2022;25:756-764.
7. Holt RIG, Peveler RC. Antipsychotic drugs and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf). 2021;95:1-12.
8. Iglesias P, Arcano K, Triviño V, García-Sancho P, Díez JJ, Villabona C. Giant prolactinoma in men: clinical features and therapeutic outcomes. Endocrine. 2018;60:308-316.
9. Indirli R, Mantovani G, Ferrante E, Arosio M. Prolactinomas and metabolic disorders: pathophysiological mechanisms and clinical implications. Front Endocrinol (Lausanne). 2022;13:1-10.
10. Karaca Z, Tanriverdi F, Unluhizarci K, Kelestimur F. Pregnancy and pituitary disorders. Eur J Endocrinol. 2019;181(1):R1-R14.

    file

    download